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Abstract The purpose of this study was to characterize the
clinical and serological features of a large cohort of patients
with antinuclear antibody (ANA) positive undifferentiated
connective tissue disease (UCTD). Consecutive patients
with UCTD, followed up at the Rheumatology Clinic of the
participating centers, were included. Data from these
patients were obtained by clinical evaluation and chart
review. All patients were diagnosed as having UCTD on
basis of the following criteria: positive ANA plus at least
one clinical feature of connective tissue disease, but not
fulfilling classification criteria for any differentiated con-
nective tissue disease. One hundred eighty-four patients
were studied (female patients—94.5%; mean age at time of
evaluation—47 years). The most prevalent manifestations
were arthralgia (66%), arthritis (32%), Raynaud’s phenom-
enon (30%), sicca symptoms (30%), and leukopenia (19%).
The prevalence of ANA was 100%, anti-SSA 20%, anti-
dsDNA 14%, and anti-SSB 7%. Patients with anti-dsDNA/
anti-Sm, anticentromere/anti-Scl70, or anti-SSA/anti-SSB
antibodies more frequently presented a set of manifestations
close to systemic lupus erythematosus (SLE), systemic
sclerosis, or Sjögren syndrome, respectively. We analyze a
large cohort of UCTD. Seventy-two percent of these UCTD
patients present lupus-, scleroderma-, or Sjögren-like
features but do not fulfill classification criteria and mostly
present a mild disease.
Keywords Classification criteria . Connective tissue
diseases . Systemic lupus erythematosus .
Undifferentiated connective tissue diseases
Introduction
Many patients present at Rheumatology Clinic because of
signs, symptoms, and laboratory abnormalities suggesting
systemic rheumatic disease, but do not meet classification
criteria of any specific connective tissue disease (CTD) or
any other well-defined disease that might justify these
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features. These syndromes are currently classified as undif-
ferentiated connective tissue disease (UCTD).
Consensual classification criteria for UCTD have not
been attained. However, Mosca et al. [1] proposed
preliminary classification criteria for UCTD, comprising
(1) patients presenting signs and symptoms suggestive of a
CTD, but not fulfilling the criteria for any of the defined
CTDs, and (2) presence of antinuclear antibodies deter-
mined on two different occasions. Additionally, those with
disease duration less than 3 years would be defined as
having an early UCTD.
There is a need for sensitive, specific, and consensual
classification set, enabling the exclusion of patients with no
autoimmune disturbance and ensuring comparability be-
tween studies. There is also a need for prognosis estimation
criteria, including risk of the disease’s progression and of
the development of severe clinical manifestations.
There is still scarcely any data regarding the possibility
to prevent progression of UCTD to a specific CTD with
immunomodulatory drugs. Interestingly, a recent prospec-
tive study of 25(OH) D3 serum levels in patients with
UCTD suggests that vitamin D deficiency in UCTD
patients may increase the rate of progression into well-
defined CTDs [2]. In SLE, early intervention with
hydroxychloroquine has been postulated to delay or prevent
the development of more serious sequelae. In another study,
UCTD patients treated with hydroxychloroquine who
subsequently progressed to systemic lupus erythematosus
had a longer lag time between the onset of the first clinical
symptom and SLE classification and also had a lower rate
of autoantibody accumulation and a decreased number of
autoantibody specificities at and after diagnosis [3].
Our study presents the characterization of the clinical
and serological profile of a large cohort of UCTD patients
followed in seven Rheumatology Units.
Materials and methods
Seven Rheumatology Outpatient Clinics participated in this
study, which represented 58% of all Portuguese centers and
covering a representative sample of the Portuguese popu-
lation. The inclusion criteria were consecutive patients
seen at the participating clinics and fulfilling the UCTD
classification criteria proposed by Mosca et al. [1], re-
gardless of the disease’s duration. Exclusion criteria were
patients fulfilling classification criteria for any differentiat-
ed CTD or any well-defined disease that justifies the
recorded clinical and analytical changes, including rheuma-
toid arthritis, systemic lupus erythematosus, systemic
sclerosis, Sjögren syndrome, psoriatic arthritis, seronegative
spondyloarthritis, juvenile idiopathic arthritis, antiphospho-
lipid syndrome, systemic vasculitis, or fibromyalgia. Clin-
ical and laboratorial data were obtained by clinical evaluation
at time of visit and retrospective analysis of patients with
UCTD diagnosis clinical charts followed up between 1989
and 2007. Antinuclear antibody (ANA) testing was requested
by the attending rheumatologist if there was a clinical
suspicion of CTD. Sera were sent to the respective center
immunology laboratory, where ANA was determined by
indirect immunofluorescence on Hep-2 cells. Titers of 1:160
or greater were considered positive. In ANA positive sera,
further testing was done. Anti-dsDNAwas evaluated by Farr
radioimmunoassay or enzyme-linked immune-absorbent
assay (ELISA), depending on the laboratory. Anti-RNP, anti-
Sm, anti-SSA, anti-SSB, anti-Jo1, anti-Scl70, and anti-
cardiolipin were analyzed in all patients with ELISA. Lupic
anticoagulant was detected by means of two triage tests using
Dilute Russell Viper Venom time. Determination of C3 and
C4 was assessed by nephelometry. A protocol chart (Table 1)
was elaborated to record each patient’s data. After screening
of inclusion and exclusion criteria, data were introduced and
analyzed in Excel®. Thirteen patients were excluded at this
point, 11 because they presented negative ANA and two
because they had an established primary antiphospholipid
syndrome. Qui-Square tests were used to analyze the
differences between groups.
Results
A total of 184 patients (94.5% female patients) was
included, mean age 47 years (16–78 years). Mean follow-
up after diagnosis, 3.04 years (up to 18 years), presented an
early UCTD 53% of the patients.
The most frequent clinical–laboratorial manifestations,
with prevalence >10%, were arthralgia (66%), arthritis
(32%), sicca syndrome (30%), Raynaud’s phenomenon
(30%), leukopenia (19%), photosensitivity (17%), anemia
(15%), oral ulcerations (14%), alopecia (13%), and arterial
hypertension (13%). Other manifestations were rare, in-
cluding major organ involvement (Table 2). Each patient
presented a mean of three clinical manifestations.
Concerning autoimmune profile, 100% presented posi-
tive ANA, as required by inclusion criteria. The majority of
patients presented positive ANA with no detectable antigen
specificity (61% of patients), 26% had autoantibodies
against a single nuclear antigen, 11% had two antigen
specificities and 3% had three. Anti-SS-A (20%), anti-
dsDNA (14%), and anti-SS-B (7%) were the most prevalent
autoantibodies. The prevalence of anti-RNP was 6%, anti-
centromere was 4%, anti-histones was 4%, anti-Sm was
2%, and anti-Scl-70 was 1%. Some patients (10%) also
presented positive anticardiolipin antibodies.
In 17% of patients, serum levels of C3 and/or C4 were
low. Of these, 18% presented anti-dsDNA, 30% anti-SSA,
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11% anti-SSB, 5% anticentromere, 5% anti-RNP, 2%
antihistones, and 30% no detectable antigen specificity of
ANA.
Many patients with UCTD included in the cohort
presented features similar to SLE, but did not fulfill, up to
the point of assessment, this disease’s classification criteria
[4, 5]. Seventy-four patients (40% of the cohort) met three
classification criteria for SLE and thus presented a lupus-
like disease. Clinical and serological characterization of this
UCTD subgroup is presented in Table 3 and compared with
the rest of the cohort. The lupus-like subgroup presented
higher frequency of arthritis, cytopenias, oral ulcers,
photosensitivity, and anti-dsDNA antibody.
The presence of anti-dsDNA was associated with
decreased levels of C3 (p=0.024) and C4 (p=0.007).
Signs and symptoms Serological manifestations
Arthralgia/arthritis ANA





Photosensitivity Ac antiphospholipid/anticardiolipin/lupic anticoagulant
Serositis Decreased C3/Decreased C4










Table 1 Protocol chart


























Arthralgia 58 54 0.047
Raynaud 35 22 n.s.
Arthritis 24 49 <0.0001
Leukopenia 12 28 0.006
Anemia 8 24 0.006
Sicca syndrome 35 28 n.s.
Photosensitivity 12 25 0.006
Serositis 0 4 n.s.
Malar rash 5 13 n.s.
Oral ulcers 8 22 0.003
Thrombocytopenia 5 14 0.035
Positive ANA 100 100 –
Anti-dsDNA 4 29 <0.0001
Anti-SSA 24 21 n.s.
Anti-SSB 10 4 n.s.
Anti-Sm 1 4 n.s
Anti-RNP 5 4 n.s.
Anti-Scl 70 1 0 n.s.
Anticentromere 5 3 n.s
Antihistones 2 5 n.s.
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Anticardiolipine antibodies related to thrombocytopenia
(p=0.014).
Only 4.8% of patients presented anticentromere anti-
bodies or anti-Scl70. The subgroup of patients with either
of these antibodies presented systemic sclerosis-like clinical
changes, with higher prevalence of Raynaud’s phenomenon
and telangiectasia and lower frequency of arthritis, as
compared with the rest of the UCTD cohort, but not
fulfilling classification criteria for systemic sclerosis (SSc)
[6–8] (Table 4). Patients with anti-SSA and/or anti-SSB
antibodies (27% of the cohort; Table 5) presented a higher
prevalence of leukopenia and sicca syndrome but not of
other clinical features suggestive of Sjögren-syndrome (SS)
[9, 10].
The remaining patients (44% of the cohort) showed mild
clinical–laboratorial changes, characterized mostly by ar-
thralgia (57%), Raynaud (32%), sicca symptoms (25%),
arthritis (24%), photosensitivity (10%), and leukopenia
(9%). In this subgroup, prevalence of anti-RNP was 7%,
anti-dsDNA was 2%, antihistones were 2%, anti-SSA was
1%, and anti-Sm 1%.
Most patients with UCTD belonging to this clinical
cohort presented mild clinical features. Hence, 46% were
not receiving treatment with immunosuppressors or immu-
nomodulators. Ongoing treatment included nonsteroidal
antiinflammatory drugs (NSAID; 53%), corticosteroids
(41%), antimalarial drugs (39%), and azathioprine (1%).
Discussion
Differentiated CTD are characterized by a wide range of
signs and symptoms that vary from patient to patient and in
each patient through time. As few clinical manifestations
are disease specific, there is a certain degree of overlapping
between the different conditions. Classification criteria
defined for each CTD permit us to identify reasonably
homogenous cohorts of patients. This is rather important in
pathogenesis research and clinical trials. Nevertheless, it is
common for patients to present signs and symptoms
suggesting CTD, but not fulfilling classification criteria
for a definite disease, which are currently classified as
UCTD.
The history of undifferentiated disease dates back to
1980 when LeRoy et al. proposed the concept of “undif-
ferentiated connective tissue syndromes”. Throughout the
subsequent 28 years, undifferentiated CTDs have been
variably defined [11]. Some cohort studies have been
published, but use of variable UCTD inclusion criteria
limits the possibility for comparison between cohorts and
raises difficulties in the extrapolation of relating results as
prognosis is concerned.
This study presents a large cross-sectional cohort of
patients with UCTD and the largest one using positive
ANA as inclusion criteria. We required the presence of
ANA, aiming to increase the specificity for an autoimmune
disorder, given the role of ANA in the pathogenesis of most
of the defined CTD. In the larger published UCTD cohorts,
those by Alarcon et al. [12] and Bodolay et al. [13], only
117 (55% of 213) and 166 (25% of 665) patients,
respectively, presented positive ANA (Table 6). Further-
more, participating rheumatologists only requested ANA
testing if there was a clinical suspicion of CTD. Indiscrim-
inate testing for ANA in patients with musculoskeletal pain
could lead to many false-positive diagnosis of UCTD, as
the frequency of positive ANA in the general population is
up to 8% [14]. Of notice, other rheumatologic conditions









Arthralgia 57 33 n.s.
Raynaud 27 89 <0.0001
Telangiectasia 2 22 0.012
Arthritis 34 0 n.s.
Leukopenia 18 22 n.s.
Anemia 15 0 n.s.
Thrombocytopenia 10 0 n.s.
Sicca syndrome 29 33 n.s.
Photosensitivity 16 11 n.s.
Serositis 2 0 n.s.
Malar rash 7 11 n.s.
Oral ulcers 14 0 n.s.
Positive ANA 100 100 –









Arthralgia 60 69 n.s.
Raynaud 33 22 n.s.
Arthritis 36 29 n.s.
Leukopenia 15 33 0.006
Anemia 16 14 n.s.
Thrombocytopenia 9 12 n.s.
Sicca syndrome 28 47 0.027
Photosensitivity 16 20 n.s.
Serositis 2 0 n.s.
Malar rash 10 2 n.s.
Oral ulcers 16 8 n.s.
Positive ANA 100 100 –
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that could justify joint pain, including fibromyalgia, were
exclusion criteria for this study.
In this study, we included patients with early UCTD
(less than 3 years) as well as patients with established
UCTD (at least 3 years duration). Established UCTD
possibly represents a cohort of patients with a more stable
clinical phenotype, which is unlikely to go into remission or
evolve to a differentiated CTD. Early UCTD patients
potentially have a more clinically unstable disease, with a
higher risk of evolving to a differentiated CTD [11].
In spite of the differences in patients’ inclusion criteria
between studies, epidemiological clinical, laboratorial, and
immunological features observed in the present study are
quite similar to those obtained in other UCTD cohorts
(Table 6). Therapeutics used in patients belonging to the
present clinical cohort is also similar to those described in
previous studies.
A fundamental question to consider is how to estimate
the prognosis of UCTD, particularly whether the clinical
situation will evolve to a defined CTD and the possibility of
foreseeing when this might occur. The published prospec-
tive studies [12–18] found an evolving frequency that
varies from 5% to 68% of patients. According to this data,
it is estimated that 20–40% of patients with early UCTD
will develop a definite CTD [11]. Development to dif-
ferentiated CTD might occur from months to years after the
first UCTD manifestations. Progression risk seems to be
higher during the disease’s first 5 years [11, 19].
UCTD might evolve to any of the different defined
CTD. Nevertheless, some clinical and laboratorial features
may suggest a higher probability of disease evolution to
occur to a certain CTD instead of others. In the present
clinical cohort, we found that patients with anti-dsDNA/
anti-Sm, anticentromere/anti-Scl70, or positive anti-SSA/
anti-SSB more frequently present a set of manifestations
close to SLE, SSc, or SS, respectively.
In our UCTD cohort, 40% presented a lupus-like
disease. In the cohort assessed by Swaak and Smeenk
[20], the positivity of anti-dsDNA antibodies was predictive
for evolution to SLE. Calvo-Álen et al. [21] noted that
alopecia, serositis, positive Coombs test, anti-dsDNA, anti-
Sm, positive test for syphilis, and ANA with homogenous
pattern correlated significantly to differentiation toward
SLE. Danieli et al. [16, 17] identified fever, anticardiolipin
antibodies, and anti-dsDNA as predictive factors for SLE.
Vila et al. [22] demonstrated that malar rash, oral ulcerations,
Table 6 UCTD clinical and serological manifestations
Alarcon [12];
N=213 (%)












Arthralgia – – 80 77 58 50 66
Raynaud 46 – 46 45 78 60 30
Arthritis 70 – 37 14 38 30 32
Leukopenia 11 – 41 – – – 19
Anemia 23 – 16 – – 30 15
Thrombocytopenia 2 – 13 – 4 11 9
Xerophthalmia 7 – 41 18 20 25 30
Xerostomia 7 – 36 18 20 25 30
Photosensitivity 10 – 30 – 22 23 17
Serositis 10 – 5 – – – 2
Malar rash 11 – 6 – – – 8
Oral ulcers 12 – 4 – – – 14
Positive ANA 55 59 100 100 58 25 100
Anti-dsDNA – 5 19 – 5 – 14
Anti-SSA – 12 30 – 14 – 20
Anti-SSB – 3 5 – 3 – 7
Anti-Sm – 3 1 – –a – 2
Anti-RNP – 14 28 – 7 – 6
Anti-Scl 70 – 0 – – –a – 1
Anticentromere – – – – –a – 4
Antihistones – – – – –a – 4
– not reported
a Positive ENA (unspecified) 27%
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anti-dsDNA positivity, and decreased C4 were statistically
significant in predicting the evolution to SLE. Cavazzana
et al. [23] noticed that leukopenia was more frequently
detected in patients who developed a definite CTD and
that anti-dsDNA was predictive of evolution to SLE.
Also in the study of Danieli et al. [16, 17], sicca
symptoms, Raynaud’s phenomenon, sclerodactylia, esoph-
ageal dysfunction, and ANA with nucleolar pattern as
predictive factors for the development of systemic sclerosis
and Raynaud’s phenomenon, xerostomia, and anti-SSA as
predicative factors for Sjögren syndrome. In our UCTD
cohort, patients with anticentromere antibodies or anti-Scl
70 presented systemic sclerosis-like clinical features, and
the ones with anti-SSA and/or anti-SSB antibodies pre-
sented a Sjögren syndrome-like disease.
In our cohort, most patients had a very limited profile of
ANA specificities, with no detectable antigen specificity in
61% of patients and just one in another 26%. Mosca et al.
[1] reported a correlation between SLE development and
the accumulation of autoantibodies. Furthermore, the
analysis of the autoantibodies specificities during follow-
up showed that UCTD patients with a stable profile do not
develop new specificities. On the contrary, patients devel-
oping SLE develop new antibody specificities during the
course of the follow-up [11]. In general, autoantibodies
might be detectable several years before the onset of
symptoms. In a study on 130 SLE patients, at least one anti-
body was present in 88% of patients before the diagnosis [24].
The best way to classify the cases with features close to
a definite CTD, like SLE, SSc, or SS, remains a matter of
debate. These may be seen either as UCTD or alternatively
as incomplete forms of a defined CTD. In an attempt to
distinguish “true” UCTD from incomplete CTD, there has
been suggested a preliminary set of exclusion criteria in
addition to classification criteria for UCTD [25]. These
included clinical manifestations and ANA reactivities
considered more specific for a definite CTD. According to
this view, incomplete forms of defined CTD would belong
to the same spectra of the related CTD and not to UCTD.
However, there are no clinical or immunological features
truly specific of a defined CTD. Excluded from the UCTD
group, the frontiers of incomplete forms of defined CTD
would remain very difficult to establish, and in practice, a
group of unclassifiable cases, neither UCTD nor defined
CTD, would remain.
Our study has some limitations. It is a cross-sectional
evaluation of patients with variable disease duration, and
those with UCTD at presentation who developed features of
a differentiated CTD before the time of this evaluation were
not included. Also, the presence of “disease specific” anti-
bodies may have taken the clinician to valuate some mani-
festations in detriment of others, constituting a potential
source of bias for the definition of UCTD subgroups.
In summary, in this study, we describe a large cohort of
UCTD patients and found that more than half of the
patients present a SLE-, SS-, or SSc-like disease. This and
previous studies of UCTD partake in predominantly mild
clinical profile and need for mostly symptomatic therapy.
According to available data, many patients with UCTD
have a favorable prognosis. However, we find it advisable
for these patients to be regularly followed up, even if only
presenting with benign manifestations, so as to detect
eventual evolution to a more severe specific CTD. There is
a need to establish better classification criteria and of long-
term observational study of UCTD cohorts to better
understand this entity and its prognosis and development of
trials of promising drugs for preventing disease progression.
Disclosures None.
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